These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36899846)

  • 21. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma.
    Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY
    Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic role of RUNX3 in head and neck cancer.
    Kudo Y; Tsunematsu T; Takata T
    J Cell Biochem; 2011 Feb; 112(2):387-93. PubMed ID: 21268058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant methylation of RUNX3 is present in Aflatoxin B
    Wang S; He Z; Li D; Zhang B; Li M; Li W; Zhu W; Xing X; Zeng X; Wang Q; Dong G; Xiao Y; Chen W; Chen L
    Toxicology; 2017 Jun; 385():1-9. PubMed ID: 28458013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer.
    Chen W; Gao N; Shen Y; Cen JN
    J Gastroenterol Hepatol; 2010 Apr; 25(4):823-31. PubMed ID: 20492341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53.
    Yamada C; Ozaki T; Ando K; Suenaga Y; Inoue K; Ito Y; Okoshi R; Kageyama H; Kimura H; Miyazaki M; Nakagawara A
    J Biol Chem; 2010 May; 285(22):16693-703. PubMed ID: 20353948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome.
    Yokomizo-Nakano T; Kubota S; Bai J; Hamashima A; Morii M; Sun Y; Katagiri S; Iimori M; Kanai A; Tanaka D; Oshima M; Harada Y; Ohyashiki K; Iwama A; Harada H; Osato M; Sashida G
    Cancer Res; 2020 Jun; 80(12):2523-2536. PubMed ID: 32341038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.
    Ito K; Lim AC; Salto-Tellez M; Motoda L; Osato M; Chuang LS; Lee CW; Voon DC; Koo JK; Wang H; Fukamachi H; Ito Y
    Cancer Cell; 2008 Sep; 14(3):226-37. PubMed ID: 18772112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras?
    Lee JW; van Wijnen A; Bae SC
    Adv Exp Med Biol; 2017; 962():321-332. PubMed ID: 28299666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.
    Kim WJ; Kim EJ; Jeong P; Quan C; Kim J; Li QL; Yang JO; Ito Y; Bae SC
    Cancer Res; 2005 Oct; 65(20):9347-54. PubMed ID: 16230397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of the tumor suppressor RUNX3 in giant cell tumor of the bone.
    Han YX; Liang DY
    Int J Oncol; 2012 Mar; 40(3):673-8. PubMed ID: 22076387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lineage-specific RUNX3 hypomethylation marks the preneoplastic immune component of gastric cancer.
    Kurklu B; Whitehead RH; Ong EK; Minamoto T; Fox JG; Mann JR; Judd LM; Giraud AS; Menheniott TR
    Oncogene; 2015 May; 34(22):2856-66. PubMed ID: 25088199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two faces of RUNX3 in myeloid transformation.
    Yokomizo-Nakano T; Sashida G
    Exp Hematol; 2021 May; 97():14-20. PubMed ID: 33600870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.
    Zhang L; Liu P; Li H; Xue F
    Mol Med Rep; 2013 May; 7(5):1705-9. PubMed ID: 23504001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
    Xu L; Lan H; Su Y; Li J; Wan J
    Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma.
    Mainardi S; Mijimolle N; Francoz S; Vicente-Dueñas C; Sánchez-García I; Barbacid M
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):255-60. PubMed ID: 24367082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
    Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
    Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells.
    Chang TL; Ito K; Ko TK; Liu Q; Salto-Tellez M; Yeoh KG; Fukamachi H; Ito Y
    Gastroenterology; 2010 Jan; 138(1):255-65.e1-3. PubMed ID: 19706291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer.
    Chen F; Wang M; Bai J; Liu Q; Xi Y; Li W; Zheng J
    PLoS One; 2014; 9(1):e86917. PubMed ID: 24475196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Runx3 and Cell Fate Decisions in Pancreas Cancer.
    Whittle MC; Hingorani SR
    Adv Exp Med Biol; 2017; 962():333-352. PubMed ID: 28299667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.